Diagnostic Accuracy of Bilateral Inferior Petrosal Sinus Sampling Using Desmopressin or Corticotropic- Releasing Hormone in Acth-Dependent Cushing’S Syndrome: A Systematic Review and Meta-Analysis Publisher Pubmed



Valizadeh M¹ ; Ahmadi AR² ; Ebadinejad A¹ ; Rahmani F³ ; Abiri B¹ Show Affiliations
Source: Reviews in Endocrine and Metabolic Disorders Published:2022

Abstract

The current gold standard diagnostic method for Cushing disease (CD) is bilateral inferior petrosal sinus sampling (BIPSS) after corticotropin-releasing hormone (CRH) stimulation. Due to shortages of CRH, BIPSS has been performed with desmopressin (DDAVP) instead. The objective of this systematic review and meta-analysis was to estimate the diagnostic accuracy of BIPSS using DDAVP or CRH for the differential diagnosis of Cushing’s syndrome (CS). A literature review was done in PubMed, Scopus, EMBASE, and google scholar databases to derive summary estimates of the overall diagnostic sensitivity and accuracy of BIPSS using DDAVP or CRH in Cushing’s syndrome. Pooled sensitivity, specificity, diagnostic odds ratio and summary receiver operating characteristic curves (SROC) for differential diagnosis of Cushing’s syndrome in the random-effects models, were computed. Overall, 11 different studies with a total of 612 participants, were eligible for the analysis. Five articles with data on BIPSS using DDAVP, 5 papers on BIPSS using CRH, and another one evaluated the results of stimulation using DDAVP, with or without CRH, for differential diagnosis of Cushing’s syndrome. The pooled (95% CI) sensitivity and specificity of BIPSS using DDAVP, were 96% (91–98%) and 1.00 (0.00–1.00), respectively. The area under the SROC curve was 0.95. The pooled (95% CI) sensitivity and specificity of BIPSS using CRH, were 98% (92–99%) and 1.00 (0.00–1.00), respectively, and the area under the SROC curve was 0.98. The I2 index (95% CI) was 0% (0–100%) for both BIPSS using DDAVP and using CRH. As a result, DDAVP stimulation is a safe, effective, less expensive, valuable and available alternative to CRH in the setting of BIPSS for all age groups of patients with CS. Registration code in PROSPERO: CRD42021292531. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.